The not-so-good prognosis of streptococcal periprosthetic joint infection managed by implant retention: The results of a large multicenter study

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3108593 36 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
The not-so-good prognosis of streptococcal periprosthetic joint infection managed by implant retention: The results of a large multicenter study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background. Streptococci are not an infrequent cause of periprosthetic joint infection (PJI). Management by debridement, antibiotics, and implant retention (DAIR) is thought to produce a good prognosis, but little is known about the real likelihood of success. Methods. A retrospective, observational, multicenter, international study was performed during 2003-2012. Eligible patients had a streptococcal PJI that was managed with DAIR. The primary endpoint was failure, defined as death related to infection, relapse/persistence of infection, or the need for salvage therapy. Results. Overall, 462 cases were included (median age 72 years, 50% men). The most frequent species was Streptococcus agalactiae (34%), and 52% of all cases were hematogenous. Antibiotic treatment was primarily using β-lactams, and 37% of patients received rifampin. Outcomes were evaluable in 444 patients: Failure occurred in 187 (42.1%; 95% confidence interval, 37.5%-46.7%) after a median of 62 days from debridement; patients without failure were followed up for a median of 802 days. Independent predictors (hazard ratios) of failure were rheumatoid arthritis (2.36), late post-surgical infection (2.20), and bacteremia (1.69). Independent predictors of success were exchange of removable components (0.60), early use of rifampin (0.98 per day of treatment within the first 30 days), and long treatments (≥21 days) with β-lactams, either as monotherapy (0.48) or in combination with rifampin (0.34). Conclusions. This is the largest series to our knowledge of streptococcal PJI managed by DAIR, showing a worse prognosis than previously reported. The beneficial effects of exchanging the removable components and of β-lactams are confirmed and maybe also a potential benefit from adding rifampin. © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America.
Έτος δημοσίευσης:
2017
Συγγραφείς:
Lora-Tamayo, J.
Senneville, É.
Ribera, A.
Bernard, L.
Dupon, M.
Zeller, V.
Li, H.K.
Arvieux, C.
Clauss, M.
Uçkay, I.
Vigante, D.
Ferry, T.
Iribarren, J.A.
Peel, T.N.
Sendi, P.
Miksić, N.G.
Rodríguez-Pardo, D.
Del Toro, M.D.
Fernández-Sampedro, M.
Dapunt, U.
Huotari, K.
Davis, J.S.
Palomino, J.
Neut, D.
Clark, B.M.
Gottlieb, T.
Trebše, R.
Soriano, A.
Bahamonde, A.
Guío, L.
Rico, A.
Salles, M.J.C.
Pais, M.J.G.
Benito, N.
Riera, M.
Gómez, L.
Aboltins, C.A.
Esteban, J.
Horcajada, J.P.
O'connell, K.
Ferrari, M.
Skaliczki, G.
Juan, R.S.
Cobo, J.
Sánchez-Somolinos, M.
Ramos, A.
Giannitsioti, E.
Jover-Sáenz, A.
Baraia-Etxaburu, J.M.
Barbero, J.M.
Choong, P.F.M.
Asseray, N.
Ansart, S.
Moal, G.L.
Zimmerli, W.
Ariza, J.
Περιοδικό:
Clinical Infectious Diseases
Εκδότης:
Oxford University Press
Τόμος:
64
Αριθμός / τεύχος:
12
Σελίδες:
1742-1752
Λέξεις-κλειδιά:
antibiotic agent; beta lactam antibiotic; rifampicin; antiinfective agent; beta lactam; rifampicin, adult; aged; antibiotic therapy; Article; bacteremia; beta hemolytic Streptococcus; coagulase negative Staphylococcus; combination drug therapy; controlled study; Corynebacterium striatum; death; debridement; Enterococcus faecalis; female; follow up; human; major clinical study; male; monotherapy; observational study; periprosthetic joint infection; priority journal; prognosis; retrospective study; rheumatoid arthritis; salvage therapy; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus anginosus; Streptococcus canis; Streptococcus constellatus; Streptococcus dysgalactiae subsp. equisimilis; Streptococcus equinus; Streptococcus gordonii; Streptococcus group G; Streptococcus infection; Streptococcus intermedius; Streptococcus milleri; Streptococcus mitis; Streptococcus mutans; Streptococcus oralis; Streptococcus parasanguinis; Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus salivarius; Streptococcus sanguinis; surgical infection; treatment duration; treatment failure; biofilm; clinical trial; debridement; drug effects; infection; infectious arthritis; international cooperation; isolation and purification; microbiology; mortality; multicenter study; prognosis; Streptococcus infection, Aged; Anti-Bacterial Agents; Arthritis, Infectious; beta-Lactams; Biofilms; Debridement; Female; Humans; Internationality; Male; Prognosis; Prosthesis-Related Infections; Retrospective Studies; Rifampin; Salvage Therapy; Streptococcal Infections; Streptococcus agalactiae; Treatment Failure
Επίσημο URL (Εκδότης):
DOI:
10.1093/cid/cix227
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.